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Transforming growth factor /B1 expression in human colorectal tumours: an
independent prognostic marker in a subgroup of poor prognosis patients
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Summary Members of the transforming growth factor ,B (TGF-fl family, in particular TGF-,B1, are some of
the most potent inhibitory growth factors in a variety of cell types. Resistance to TGF-f,l-induced growth
inhibition is frequently observed in colorectal carcinomas and is associated with tumour progression.
Perturbations of TGF-,B1 expression and function, therefore, may contribute to the loss of some constraints on
tumour cell growth. In this study we have examined the expression of TGF-f,l and its precursor latency-
associated peptide (LAP)-TGF-f, in human colorectal tumours using immunohistochemical techniques. In 86%
of the tumours the LAP-TGF-,B complex was present in both the stromal and epithelial cells, whereas the
mature TGF-fll peptide was expressed in the glandular epithelium of 58.3% of these tumours. Intense staining
for TGF-,B1 was positively associated with advanced Dukes' stage. Furthermore, there was a significant
correlation between the presence of TGF-f,l in the tumours and a shorter post-operative survival. This was
most significant in a subgroup of patients who had received only a palliative operation. These results suggest
that TGF-,B1 expression may be useful as an independent prognostic indicator for a subgroup of patients who
have a particularly poor prognosis.
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Colorectal cancer remains a major cause of mortality in
Britain and although resectional surgery is the mainstay of
treatment, 60% of patients still die within 5 years as a result
of distant metastasis or local recurrence (Schofield et al.,
1986). While adjuvant radio- and chemo-therapy have
improved recurrence-free survival (O'Connell and Gunder-
son, 1992; Wolmark et al., 1993; Kohnewompner et al., 1994;
Schmoll, 1994), these combinations fail to have a significant
effect either in those patients who present with Dukes' stage
B disease, or on overall patient survival. Since only a
minority of patients benefit from the adjuvant treatment
modalities, better selection of those at high risk of recurrence,
who would gain the major benefits from adjuvant treatment
is required.
Surgical and pathological staging can identify groups of
colorectal cancer patients likely to be at a higher risk of
tumour relapse and death (Rothenberger, 1993). However, it is
clear that even within these groups, there are subsets of
patients with a better or worse prognosis than the group as a
whole. The need to identify these subsets ofpatients has led to
the measurement of numerous other variables such as DNA
content (Jass et al., 1989), proliferative index and the tumour
doubling time (Khan et al., 1988), which have been related to
patient outcome. It is now clear that these factors are little
better than the conventional pathological staging procedures.
The transforming growth factor # (TGF-f) gene super-
family consists of several polypeptide isoforms, of which
TGF-f,l is the most abundant (reviewed in Massague et al.,
1992; Lahm and Odartchenko, 1993). TGF-fs are secreted as
latent high molecular weight complexes comprising the latent
TGF-,B binding protein (LTBP), the latency-associated
peptide (LAP) and the mature TGF-,B peptide (reviewed in
Harpel et al., 1992). The LTBP is thought to be an important
molecule for the correct assembly and secretion of TGF-il.
Once secreted, TGF-,Bl remains inactive in a non-covalent
association with LAP, in what has been termed the 'small
latent complex'. Activation occurs via the proteolytic
cleavage of the mature peptide from this complex (Odekon
et al., 1994), although the ability of LAP to reassociate with
TGF-#J1 is important in regulating its availability (Wakefield
et al., 1989). In its active form, TGF-f11 inhibits the growth
of epithelial cells but stimulates mesenchymal cell prolifera-
tion and cell migration (reviewed in Massague et al., 1992).
In the colon, TGF-,B appears to arrest proliferation of
enterocytes as they leave the intestinal crypt and move to the
villus tip. Indeed, TGF-,B immunoreactivity, which is
restricted largely to the epithelial cells of human colonic
crypts, is maximal in the upper regions of the crypts
compared with cells in the proliferative compartment
(Avery et al., 1993), supporting the concept of TGF-f as a
feature of the differentiated phenotype. Immunoreactivity was
present in normal large bowel mucosa as well as colorectal
carcinomas and adenomas (Avery et al., 1993), which offers
no explanation for the observation that the loss of
responsiveness to the inhibitory effects of TGF-f,l in human
colonic epithelial cell lines, is related to the degree of
malignancy of the cells (Manning et al., 1991). It is
interesting, however, that the first report of TGF-#
immunoreactivity, made in thyroid epithelium (Jasani et al.,
1990), demonstrated positive staining in malignant but not in
benign or normal tissues. In addition, data from clinical
studies have positively associated TGF-#l expression in vivo
with the increased invasiveness in breast (Osamura et al.,
1990; Gorsch et al., 1992) and prostate cancer (Steiner and
Barrack, 1992; Thompson et al., 1992) and reduced survival
in pancreatic carcinomas (Friess et al., 1993).
In order to determine whether TGF-fJ1 expression could
be of prognostic value in colorectal cancer we have examined
the relationship between the expression of both the TGF-fB1
peptide and LAP-TGF-31 in colorectal tumours, other
known prognostic indicators and patient survival. TGF-f1
was overexpressed in a group of patients with a particularly
poor prognosis and was associated with a reduced survival.
We suggest that TGF-,ll may be a useful prognostic
indicator for the selection of patients who would benefit
from more aggressive adjuvant treatments.
Materials and methods
Patient and tissue specimens
Specimens of colorectal adenocarcinomas were obtained from
72 patients and the clinical and histological data for these
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patients were recorded. The grade of malignancy was
histopathologically classified according to a modified Dukes
stage. The completeness of resection (i.e. surgical cure) was
assessed by the operating surgeon. All the patients entered
the study at the operation date and have been followed up
for local recurrence and/or metastasis and survival for at
least 3 years.
Samples of tissue, taken as soon as the operative or biopsy
specimens became available, were fixed overnight in 4%
formalin and then paraffin embedded for immunohistochem-
ical analysis of TGF-,B1 expression. Immediately adjacent
blocks of tumour were snap frozen in liquid nitrogen for
subsequent immunohistochemical analysis using an antibody
against the TGF-,ll latency-associated peptide (LAP).
Antibodies
A goat polyclonal antiserum, prepared against recombinant
human TGF-,Bl latency-associated peptide rhLAP-TGF-#f,
was obtained from R&D Systems (Oxon, UK). This
antibody has been fully characterised and shown specifically
to detect latent TGF-fil in immunohistochemical analysis
(Barcellos-Hoff et al., 1994). In direct ELISA and Western
blot assays this antibody is specific for the LAP derived
from the TGF-,B1 precursor but does not react with LAP
from the TGF-,B2 precursor. The rhLAP-TGF-1l antibody
was used to provide a differential in the immunodetection
methods against active TGF-,iB. A chicken polyclonal
antiserum prepared against recombinant human TGF-/1
was also obtained from R&D Systems. This antibody
neutralises the biological activity of rhTGF-,1l, pTGF-,lB
and pTGF-B1.2 and was used in our studies to detect the
active form of TGF-,B1.
Immunohistochemical analysis using an anti-TGF-f,1 antibody
Sections (3 ,um) of formalin-fixed, paraffin-embedded sam-
ples were dewaxed in xylene and rehydrated through ethanol
before the blocking of endogenous peroxidase activity with
3% v:v hydrogen peroxide in methanol for 15 min at room
temperature (RT). The sections were washed in phosphate-
buffered saline (PBS, pH 7.4) and treated with hyaluronidase
(1 mg ml-' in 0.15 M sodium chloride; 0.1 M sodium acetate
pH 5.5; Sigma, Poole, UK) for 30 min at RT. Following a
5 min wash in PBS the sections were incubated with 10%
normal goat serum (NGS; Vector, Peterborough, UK) in
PBS buffer for 1 h at RT to eliminate any non-specific
staining before an overnight incubation at 4°C with a
specific chicken anti-TGF-#l antibody (R&D Systems)
diluted 1:250 in PBS buffer plus 1% NGS. In the negative
controls, chicken serum in PBS buffer was substituted for
the primary antibody. Following extensive washing in PBS,
bound antibody was detected by the addition of a
biotinylated goat anti-chicken antibody (Vector) diluted
1:400 in PBS buffer for 30 min at RT followed by exposure
to preformed avidin-biotinylated peroxidase complex (ABC;
Vector) for 30 min at RT. Sites of peroxidase reactivity were
visualised with diaminobenzidine tetrahydrochloride (DAB)
plus 0.2% (v.v) hydrogen peroxide followed by washing in
tap water. Finally the sections were counterstained with 5%
haematoxylin, dehydrated, cleared in histoclear and mounted
in DPX mounting medium.
Immunohistochemistry using an anti-LAP-TGF-f3l antibody
Sections (7 ,um) cut from snap-frozen material were fixed in
3.7% paraformaldehyde for 15 min and washed for 3 x 5 min
with 0.1 M glycine in PBS. Endogenous peroxidase activity
was blocked by incubating the slides in 3% v:v hydrogen
peroxide in methanol for 10 min at RT. Following two 5 min
washes in PBS, non-specific binding was blocked by
incubating the sections with 0.5% casein in PBS for 1 h at
RT. Excess solution was blotted from the sections which were
then incubated overnight at 4°C with a goat anti-human LAP
(TGF-,B1) antibody (R&D Systems) diluted 1:200 in PBS. In
the negative controls blocking buffer substituted for the
primary antibody. Following extensive washing in PBS,
bound antibody was detected by the addition of a
biotinylated rabbit anti-goat antiserum (Vector) diluted
1:250 in PBS for 30 min at RT followed by exposure to
preformed ABC for 30 min at RT. Immunoreactivity was
visualised as described above before the sections were
dehydrated, cleared and mounted.
Scoring
Both immunocytochemical methods produced heterogeneous
brown cytoplasmic staining. The stained sections were scored
manually using a light microscope at x400 magnification.
The degree of staining for both immunohistochemical
methods was divided into three grades; negative (-),
positive (+) and strongly positive (+ +). Strong positivity
was defined as TGF-fil staining in the majority (>80%) of
cancer cells, which was more intense than that of stromal
fibroblasts.
Statistical analysis
Correlations between TGF-f1 expression and the clinico-
pathological features of the tumours were tested using the
chi-squared (X2) test. Overall survival curves were constructed
by the method of Kaplan and Meier. We used a regression
analysis to evaluate the effects of TGF-#l status on the
incidence of recurrence and death from colorectal carcinoma
while considering other prognostic factors.
Results
The relationship between clinicopathological findings and the
expression of TGF-ll was determined in 72 colorectal
tumours. Patient ages ranged from 32-92 years (mean, 70
years). There were more male than female patients and more
rectal than colonic tumours in the study, although the ratio
of male-female patients or rectal-colonic tumours was not
significantly different between TGF-f expressors and non-
expressors (Table I).
Immunohistochemical analysis with an anti-LAP-TGF-13I
antibody
All but ten of the tumours showed positive staining (+, + +)
with the anti-LAP-TGF-,B1 antibody (Figure 1), which
stained both epithelial and stromal cells. There was wide
intertumoral heterogeneity, with an epithelial staining ranging
from strongly positive (+ +) to negative (-). A similar
variation was also seen in stromal cells. All tumours which
were negative for LAP-TGF-fB1 showed no positive staining
when using the specific anti-TGF-#1 antibody. The presence
ofLAP-TGF-#l, therefore, was not significantly correlated to
any of the prognostic variables tested, i.e. histological grade,
Dukes' stage or DNA ploidy.
Table I Age and sex of the patients according to TGF-,B1 status
TGF-fJ + TGF-fl- No.
No. of patients 42 30 72
Sex
Male 28 19 47
Female 14 11 25
Mean age (years) 67.0 67.5
Range (years) (32-92) (37-81)
Tumour type
Rectal 29 22 51
Colonic 12 9 21TGF-J1 expression in colorectal tumours
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Immunohistochemical analysis with an anti-TGF-fi1 antibody
Using the TGF-,B1 specific antibody, we found TGF-#1-
immunoreactive cells (+, + +) in 42 (58.3%) of the 72
specimens from patients with colorectal cancer. The pattern
of TGF-#l immunoreactivity was detected mainly in the
cytoplasm of the glandular epithelium (Figure 2a). Normal
tissue adjacent to the tumour showed no similar staining
patterns (Figure 2b). There were no significant correlations
between the expression of TGF-,B1 and the histological grade,
curative/palliative resection and DNA ploidy (Tables III, IV
and V). The TGF-31 status of Dukes' A and B tumours was
identical, although significantly more Dukes' C and D
tumours were TGF-fll-positive (Table II) (X2=8.03, d.f. =3,
P<0.05).
Survival
Overall, patients with TGF-,11-positive tumours had a greater
relative risk of death compared with those whose tumours
were TGF-fl1-negative. Altogether 80% of patients with
TGF-,B1-negative tumours survived 3 years compared with
only 40% of those with TGF-f,1-positive tumours (X2= 8.94,
1 d.f., P=0.003). Figure 3a shows the Kaplan-Meier
survival curves for these two groups of patients. In the
patients considered to have had curative resections, the 3 year
survival rate was 95% for the 13 patients with TGF-,B1-
negative tumours, although there was no significant difference
between these and the 18 patients with TGF-fll-positive
tumours, whose 3 year survival rate was 75% (Figure 3b).
There was, however, a highly significant survival advantage
for patients with TGF-f1l-negative tumours within the
Figure 1 Immunohistochemical staining of LAP-TGF-,B1 in a
colorectal tumour specimen. Strong positive staining can be seen
in the cytoplasm of the majority of carcinoma cells. (haematox-
ylin counterstain, original magnification x 160).
Figure 2 Immunohistochemical staining of the TGF-,11 protein
in (a) a colorectal tumour specimen, showing strong positive
staining in the cytoplasm of the glandular epithelium (original
magnification x 160) and (b) a colorectal tumour specimen with
adjacent normal tissue. Immunoreactivity can be seen in the
cytoplasm of the malignant epithelium only (original magnifica-
tion x 100, haematoxylin counterstain).TGF-fl expression in colorectal tumours
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subgroup who received only a palliative resection. In these
patients the 3-year survival rate was 60% in those with TGF-
fI-negative tumours compared with 5% for 24 patients with
TGF-ll-positive tumours (X2=6.82, 1 d.f., P=0.009) (Figure
3c).
Discussion
expression was increased in the more aggressive Dukes' C
and D tumours but there was no correlation with other
prognostic factors such as histological grade or ploidy. These
findings are in agreement with those of other studies where
overexpression of TGF-PI is associated with disease
progression and tumour recurrence in breast, prostate and
pancreatic cancers (Gorsch et al., 1992; Walker and Dearing,
1992; Steiner and Barrack, 1992; Freiss et al., 1993). The
Normal cells are induced to proliferate by the actions of
multiple growth factors and it is the mutation or aberrant
expression of components of the pathways by which these
factors act that is thought to be involved in malignant
transformation. Thus, measurement of the levels of growth
factors, their receptors or the biochemical events that they
activate in malignant tumours may provide important
prognostic or diagnostic information. TGF-fI is a principal
regulator in normal cell growth and function and also has an
important role in angiogenesis, immunosuppression, forma-
tion of the extracellular matrix and tumorigenesis. Evidence
would suggest that the control of tissue TGF-,B levels is of
critical importance since transgenic mice overexpressing
TGF-fI die in the perinatal period and 'knockout' mice
lacking the gene for TGF-j1 die within a few weeks of birth
(McCartney-Francis and Wahl, 1994). Several studies indicate
that tumour cells have an increased synthesis of TGF-f
compared with their normal counterparts (Hirayama et al.,
1992; LaRocca et al., 1992; Walker and Dearing, 1992). This
implies that high levels of TGF-,B favour tumour growth and
progression.
In our panel of colorectal specimens we showed a
significant positive correlation between TGF-,ll expression
in the tumour epithelium and Dukes' stage. TGF-/1
Table II Dukes' classification and TGF-fi1 status in 72 patients
with colorectal cancer
No. A B C D
TGF-f31+ 42 2 16 11 13
TGF-fll- 30 3 17 5 5
Total 72 5 33 16 18
x2=8.03, d.f. =3, P<0.05.
Table III Histological grade and TGF-fI status in 72 patients with
colorectal cancer
No. Well Moderate Poor
TGF-flI+ 42 9 24 9
TGF-p1- 30 9 14 7
Total 72 18 38 16
%2=0.888, d.f. =2, P=NS.
Table IV 'Curative' resection and TGF-/31 status in 72 patients with
colorectal cancer
No. Curative Palliative
TGF-fll+ 42 19 23
TGF-f31- 30 16 14
Total 72 35 37
X2=0.448, d.f. = 1, P=NS.
Table V DNA ploidy and TGF-fll status in 72 patients with
colorectal cancer
No. Diploid Aneuploid
TGF-,B1+ 42 17 25
TGF-f,l- 30 16 14
Total 72 33 39
x2= 1.166, d.f.= 1, P=NS.
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overexpression of TGF-fi1 in a human breast cancer cell line.
in vitro. markedly enhances the ability of these cells to form
tumours in athymic mice. an effect which is abolished by anti-
TGF-f antibodies (Arteaga et al.. 1993).
The overall survival time of our panel of colorectal cancer
patients was significantly shorter in those with TGF-ll-
positive tumours. This has also been shown in pancreatic
tumours where a shorter post-operative survival time is seen
in patients with TGF-13-positive tumours (Freiss et al.. 1993).
In our study. the relationship between tumour TGF-f1
positivity and poor prognosis was most significant in a
subgroup of patients that had received only a palliative
operation. A palliative resection of advanced colorectal
cancer provides good relief of local symptoms but the
outlook for these patients is poor and there is little evidence
of a prolonged survival (Baigrie and Berry, 1994). The ability
to subdivide further the patients of a particularly poor
prognosis group provides a basis for deciding which patients
are most likely to benefit from more aggressive adjuvant
treatment.
All the tumours except ten expressed the latent TGF-f1l as
assessed by an anti-LAP-TGF-ll antibody. As the latent
TGF-ll is the precursor of active TGF-#f. this implies that
the tumours with the ability to activate the latent form of
TGF-f1 are those with a poorer prognosis. This leaves us
with the question, why are those tumours that can activate a
growth-inhibitory peptide most likely to proliferate and
metastasise?
There are a number of ways in which cells may become
resistant to the growth effects ofTGF-fl. One is that there is
a defect in the high-affinity cell surface receptors for TGF-#f.
In colorectal cancer cells. expression of TGF-f receptors is
well documented (reviews in Lahm and Odartchenko. 1993:
Miyazono et al.. 1994). The human colonic cancer cell lines
SW620 and Widr can both bind TGF-f and the Widr cell line
also produces low levels of TGF-f receptor competing
activity (Coffey et al.. 1986). High-affinity binding is caused
by the presence of three molecules termed the type I. II and
III receptors. Evidence suggests that the type I and type II
receptors form a heterodimer that is crucial for the effects on
growth whereas the type I receptor alone is responsible for
effects on the extracellular matrix (Geiser et al.. 1992: Chen et
al.. 1993). However. colorectal carcinoma cell lines do not
respond to TGF-,B (Murthy et al.. 1989: Chakrabarty et al..
1990) even though they express all three types of receptor at
levels similar to their normal counterparts (Mulder et al..
1988: Manning et al.. 1991). However. a recent study has
described a subset of colon cancer cell lines in which the type
II TGF-# receptor is mutated and inactive (Markowitz et al..
1995). The mutations in the type II TGF-3 receptor gene
were observed in colon cancer cell lines with high rates of
microsatellite instability. Thus. by allowing the escape of cells
from TGF-/3-mediated growth control it is possible that the
type II receptor mutation encourages tumour progression
associated with genomic instability.
Failure to activate secreted TGF-/31 is also unlikely as we
were able to show that only the tumours expressing activated
TGF-fIl had a poor prognosis. Furthermore. it has been
shown that overproducers of either the active or the latent
form of TGF-# are unresponsive even to exogenously added
TGF-# in in vitro assays (Arrick et al., 1992). Thus. the
mechanisms underlying the loss of responsiveness to TGF-f
remains unknown. but it may be a key event in the
progression of human colorectal carcinomas.
In conclusion. our findings suggest that TGF-ll expres-
sion is associated with tumour aggressiveness. disease
progression and overall poor survival in patients with
colorectal carcinomas. The mechanisms underlying the
acquisition of resistance to the growth-inhibitory effects of
TGF-# by cancer cells is unclear, but the poor survival of
those with TGF-13l-positive tumours may be associated with
the wound healing response and further progress is likely to
be made as we reach a better understanding of the
mechanisms of action and interaction with other grow-th
factors.
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